Report cover image

Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market in China 2023

Published May 23, 2023
Length 37 Pages
SKU # GCC17999997

Description

Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market in China 2023

Antibiotics for multidrug-resistant Gram-positive bacteria are a critical area of research and development as these types of bacteria have developed resistance to multiple types of antibiotics, making them difficult to treat. Some antibiotics that have been effective in treating certain types of multidrug-resistant Gram-positive bacteria include daptomycin, linezolid, teicoplanin, and tigecycline. The antibiotics for multidrug-resistant gram-positive bacteria market in China is anticipated to increase by USD 3.0 billion till 2029 at an average annual growth of 8.58 percent as per the latest market estimates.

This industry report offers market estimates of the China market, followed by a detailed analysis of the type, and route of administration. The China market data on antibiotics for multidrug-resistant gram-positive bacteria can be segmented by type: daptomycin, linezolid, teicoplanin, tigecycline. Antibiotics for multidrug-resistant gram-positive bacteria market is further segmented by route of administration: injectable, oral.

The competitive landscape of the industry has also been examined along with the profiles of the key players Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., North China Pharmaceutical Company Ltd., Pfizer Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd.

The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.

Why buy this report?
  • Get a detailed picture of the China Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market
  • Identify segments/areas to invest in over the forecast period in the China Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market
  • Understand the competitive environment, the market’s leading players
  • The market estimate for ease of analysis across scenarios in Excel format.
  • Strategy consulting and research support for three months.
  • Print authentication provided for the single-user license.
  • Table of Contents

    37 Pages
    Part 1. Summary
    Part 2. Introduction
    Study period
    Geographical scope
    Market segmentation
    Part 3. Antibiotics for multidrug-resistant gram-positive bacteria market overview
    Part 4. Market breakdown by type
    Daptomycin
    Linezolid
    Teicoplanin
    Tigecycline
    Part 5. Market breakdown by route of administration
    Injectable
    Oral
    Part 6. Key companies
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
    North China Pharmaceutical Company Ltd.
    Pfizer, Inc.
    Zhejiang Hisun Pharmaceutical Co., Ltd.
    Zhejiang Medicine Co., Ltd.
    Part 7. Methodology
    How Do Licenses Work?
    Head shot

    Questions or Comments?

    Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.